OLMA News and Press, Olema Pharmaceuticals Inc.

2024-06-17 11:58:18 ET Summary Olema Pharmaceuticals is focused on developing palazestrant and OP-3136 for women with cancer, with FDA Fast Track designation for palazestrant. Palazestrant is currently being evaluated in a Phase 3 clinical trial for ER+/HER2- advanced or metastati...

2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-04 16:02:02 ET More on Markets Goldman Sachs: Core inflation will cool to 2.2% in developed economies Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) The Reversal Of The Reversal S&P 500 Investor Focus Shif...

2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-04 14:03:15 ET Read the full article on Seeking Alpha For further details see: Pfizer data for breast cancer therapy sends Olema higher

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 22.89% on the day to $11.89. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, d...

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s c...

2024-05-15 09:25:53 ET Gainers: SINTX Technologies ( SINT ) +186% . Faraday Future Intelligent Electric ( FFIE ) +82% . Edible Garden AG EDBL +82% after Q1 earnings release . AERWINS Technologies ( AWIN ) +33% . Greenwave Technology Solu...

Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy 85% clinical benefit rate (CBR) observed to date across all CBR-elig...